Rani Therapeutics Holdings, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Amounts are in U.S. dollars; financial statement amounts below are in millions unless otherwise noted.
Business context
Rani is a clinical-stage biotherapeutics company developing the RaniPill oral delivery platform as an alternative to injections. RaniPill GO is designed for doses up to 3 mg; the preclinical RaniPill HC is intended for payloads up to 20 mg. The company has no approved products and reported no commercial product revenue.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No commercial product revenue | No commercial product revenue | No commercial product revenue | No commercial product revenue |
| Research and development expense | $11.2 | $9.1 | $32.0 | $26.2 |
| General and administrative expense | $6.6 | $7.2 | $20.6 | $19.7 |
| Total operating expenses | $17.9 | $16.3 | $52.7 | $46.0 |
| Net loss | $18.3 | $16.2 | $53.8 | $46.0 |
| Net loss attributable to Rani Holdings | $9.2 | $8.0 | $26.9 | $21.8 |
| Basic and diluted loss per Class A share | $0.36 | $0.33 | $1.06 | $0.93 |
- Operating expenses rose 9% in Q3 and 15% year to date. The company attributed higher R&D costs mainly to preclinical and clinical work; Q3 G&A declined due to lower third-party public-company compliance costs.
- Net cash used in operating activities was $38.8 million for the first nine months, versus $31.9 million a year earlier. Capital expenditures were $1.1 million.
- At September 30, cash and cash equivalents were $5.0 million and marketable securities were $55.6 million, totaling $60.5 million. Total current assets were $63.2 million and current liabilities were $7.3 million.
- Long-term debt had a $29.3 million carrying value ($30.0 million principal); $1.2 million was classified as current. The debt bears a variable rate with a 15.48% effective rate at quarter-end, is secured by substantially all assets, and principal repayments begin in 2024. The company reported covenant compliance and no defaults.
- No profitability or operating margin is reported; the company remains loss-making and expects ongoing operating losses and negative operating cash flows.
Material changes and developments
- Compared with Q3 2022, net loss attributable to Rani Holdings increased 16%; for the first nine months it increased 23%. Year-to-date operating cash use also increased.
- September 2023 preclinical studies of RaniPill HC reported 18 successful teriparatide deliveries out of 20. Two later studies reported 10 of 10 successful antibody deliveries in canines. These are preliminary animal results, not human efficacy evidence.
- Rani initiated a Phase 1 trial of RT-111 in September 2023; topline results were expected early in Q1 2024. The company expected to begin a Phase 2 RT-102 trial in Q4 2023. It targeted potential Phase 1 readiness for RaniPill HC in the second half of 2024.
- After quarter-end, the company announced a strategic prioritization: RT-105 and RT-110 were paused and RT-101 was terminated. A November 2023 workforce reduction of approximately 25% was expected to cost about $0.3 million, mostly cash severance, and be substantially complete by the end of Q1 2024.
Outlook, risks and unusual items
- Management stated that available cash, cash equivalents and marketable securities were expected to fund operations for at least 12 months from issuance of the financial statements. The company nevertheless expects to need substantial additional capital; financing may be unavailable or dilutive and could require delays, reductions or termination of development programs.
- The filing describes significant clinical, regulatory, manufacturing, funding and commercialization uncertainty. The company depends on third parties for drug substances and certain components, and some suppliers are single-source.
- Four European patents are subject to opposition proceedings brought by Novo Nordisk. The company said outcomes were not considered probable or estimable as a loss, but adverse decisions could weaken European patent protection.
- A possible Tax Receivable Agreement payment was not recorded because realization of related tax benefits was not considered probable. Potential payments were estimated to range from zero to $23.0 million, depending on future taxable income and other factors.
- After quarter-end, Rani entered into a lease for 33,340 square feet in Fremont, California, with a 63-month initial term and base rent of $95,019 per month, increasing 4% annually, plus additional operating costs. The CEO’s annual salary was reduced from $520,000 to $100,000 through December 2024, or until specified financing or partnering proceeds are received.
- Management reported effective disclosure controls at a reasonable assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Liquidity figure: The financial statements and liquidity discussion show $60.5 million of cash, cash equivalents and marketable securities at September 30, 2023. A separate MD&A passage says $74.6 million; reconcile this apparent inconsistency against the filed statements.
- Track actual cash burn, subsequent financing, and whether the stated 12-month runway remains valid after the workforce reduction, program reprioritization and new lease.
- Verify trial timing and outcomes for RT-111 and RT-102, and whether the preclinical RaniPill HC results translate to human safety, reliability and drug exposure.
- Assess the high-cost secured debt, variable interest rate, repayment schedule and any future covenant or liquidity constraints.
- Monitor the European patent opposition decisions, the status of Celltrion arrangements following the RT-105 pause, and any future TRA liability.